Get to know our clinical trials

Clinical trial of rozanolixizumab in adults with persistent or chronic primary immune thrombocytopenia.

THE PURPOSE OF THIS STUDY IS TO FIND OUT HOW EFFECTIVE ROZANOLIXIZUMAB IS IN ACHIEVING AND MAINTAINING AN ADEQUATE PLATELET COUNT IN STUDY PARTICIPANTS WITH TIP. THE STUDY WILL ALSO EXAMINE HOW SAFE THE DRUG IS AND HOW WELL IT IS TOLERATED BY THE PARTICIPANTS. IT WILL ALSO EXAMINE HOW ROZANOLIXIZUMAB BEHAVES IN THE HUMAN BODY, I.E. HOW THE BODY REACTS TO IT.

Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ROZANOLIXIZUMAB IN ADULTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA. IMMUNOTHERAPY
  • Code EudraCT: 2019-003451-11
  • Protocol number: TP0006
  • Promoter: UCB Biopharma SRL
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.